CYTK vs VNDA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VNDA Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vanda Pharmaceuticals Inc. (VNDA) driven by superior Valuation, Growth & Margin, Momentum & Technical while CYTK counters with relative strength in Options & Structure. Fundamentally, CYTK trades at 117.7x Forward P/E with -625.2% operating margin (+2356.5% YoY revenue) versus VNDA at 103.1x Forward P/E and -77.6% operating margin (+24.1% YoY). In options structure, CYTK sits in BREAKDOWN (28th %ile IV; Dealer Gamma Walls on Pro) against VNDA sits in BREAKDOWN (75th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CYTK Revenue | VNDA Revenue | CYTK Op. Margin | VNDA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | $190M | -282.3% | 11.3% | VNDA |
| FY2019 | $30M | $230M | -368.0% | 10.0% | VNDA |
| FY2020 | $60M | $250M | -168.3% | 11.0% | VNDA |
| FY2021 | $70M | $270M | -264.5% | 15.7% | VNDA |
| FY2022 | $90M | $250M | -342.8% | 2.5% | VNDA |
| FY2023 | $10M | $190M | -6589.7% | -7.2% | VNDA |
| FY2024 | $20M | $200M | -2902.7% | -20.5% | VNDA |
| FY2025 | $90M | $220M | -695.4% | -70.0% | VNDA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CYTK | VNDA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $7.8B | $238.9M | Larger Scale | CYTK |
| Trailing P/E Ratio Valuation | 117.7x | 103.1x | Lower Multiple | VNDA |
| Forward P/E Ratio Valuation | 117.7x | 103.1x | Lower Multiple | VNDA |
| Revenue Growth (YoY) Growth | +2356.5% | +24.1% | Higher Growth | CYTK |
| Operating Margin (TTM) Profitability | -625.2% | -77.6% | Higher Margin | VNDA |
| Net Profit Margin Profitability | 0.0% | -119.9% | Higher Margin | CYTK |
| Return on Equity (ROE) Capital Efficiency | -572.1% | -82.5% | Higher ROE | VNDA |
| 52-Week Range Position Momentum | 1% ($53โ$88) | 4% ($4โ$10) | Stronger Trend | VNDA |
| Beta / 30D Volatility Risk Regime | 1.09ฮฒ ยท 58% Vol | 1.25ฮฒ ยท 61% Vol | Lower Realized Risk | CYTK |
| Unified Institutional Score Composite Signal | 57.6 / 100 (HOLD) | 49.0 / 100 (HOLD) | Higher Composite | CYTK |